We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Regulatory News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 17.75
Bid: 17.50
Ask: 18.00
Change: 0.00 (0.00%)
Spread: 0.50 (2.857%)
Open: 17.75
High: 17.75
Low: 17.75
Prev. Close: 17.75
OPTI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

OptiBiotix obtains BRC accreditation

5 Jan 2022 07:00

RNS Number : 4249X
OptiBiotix Health PLC
05 January 2022
 

OptiBiotix Health plc

("OptiBiotix" or the "Company" or the "Group")

 

OptiBiotix obtains British Retail Consortium accreditation

One of the leading international food safety standards

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing unique science and human study-based compounds that modulate the microbiome to address metabolic syndrome and diabetes, systemic low-grade inflammation, obesity, cardiovascular disease, high cholesterol and to support healthy aging has achieved British Retail Consortium ('BRC') accreditation.

 

BRC was the first standard to meet the Global Food Safety Initiative ('GFSI') benchmark, which means it is accepted by many of the world's biggest retailers, such as Tesco and Walmart. The certification ensures customers have confidence in OptiBiotix's products and it allows the Company to do business with those retailers, manufacturers, ingredients companies and food service organisations who specify certification as part of their approval process (most large retailers and their suppliers). It incorporates food safety management systems and internationally accepted best practice to ensure the safety and quality of products and in doing so reduces the risk of recalls.

 

René Kamminga, CEO of OptiBiotix Limited, commented: "We are very pleased to announce our BRC accreditation which supports our commercial strategy of selling final product solutions to partners in the retail channel containing our science backed pro and prebiotic ingredients. I am particularly proud of our team which achieved this accreditation in a relatively short period of time."

 

For further information, please contact:

 

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below

 

 

 

 

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 

 

 

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

 

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRASSUFWLEESEFF
Date   Source Headline
11th Jul 20227:00 amRNSJoint development agreement signed with Firmenich
1st Jul 20227:00 amRNSDirector Appointment and Director Dealing
28th Jun 20227:00 amRNSFinal Results
20th Jun 20227:00 amRNSProBiotix Health - Appointment of CEO
31st Mar 20227:01 amRNSAdmission of ProBiotix Health plc to AQSE
25th Mar 20222:36 pmRNSDirector/PDMR Shareholding
18th Mar 20222:00 pmRNSPrice Monitoring Extension
17th Mar 20227:00 amRNSIntention to list ProBiotix Health on AQSE
9th Mar 20227:00 amRNSExercise of warrants
1st Mar 20227:00 amRNSCommercial Appointments
28th Feb 20227:00 amRNSTrading Update
9th Feb 20227:00 amRNSCommercial and strategy update
1st Feb 20227:00 amRNSConsumer study of LPLDL in Cholbiome products
27th Jan 202210:38 amRNSExercise of Warrants
18th Jan 20227:00 amRNSPublication of third human study on LPLDL
7th Jan 20227:00 amRNSIssue of options
5th Jan 20227:00 amRNSOptiBiotix obtains BRC accreditation
15th Dec 20217:00 amRNSExclusive sales and distribution agreement
9th Dec 20217:00 amRNSLaunch of GoFigure range with Apollo Hospitals
1st Dec 202112:00 pmRNSInvestor presentation
1st Dec 20217:00 amRNSLaunch of LeanBiome with global nutrition leader
17th Nov 20217:00 amRNSFormation of OptiBiotix Health India
15th Nov 20214:59 pmRNSHolding(s) in Company
25th Oct 20217:00 amRNSSlimBiome® Approved by Health Canada
30th Sep 20217:00 amRNSHalf-year Report
1st Sep 20217:00 amRNSDirector/PDMR Shareholding
31st Aug 20217:00 amRNSDirector dealing
31st Aug 20217:00 amRNSInvestor update
10th Aug 20217:00 amRNSExtension of territories for Seed Health’s DS-01
5th Aug 20217:00 amRNSTrading and commercial update
9th Jul 202110:49 amRNSResult of AGM
6th Jul 20217:00 amRNSFurther sales expansion in Asia
17th Jun 20217:00 amRNSFinal Results
19th May 20212:00 pmRNSSkinBioTherapeutics plc shareholding
21st Apr 20217:00 amRNSDirector/PDMR Shareholding
16th Apr 20217:00 amRNSDirector’s Dealing
23rd Mar 20217:00 amRNSDirectorate Changes
17th Mar 20217:00 amRNSCommercial strategy update
2nd Mar 20217:00 amRNSDirector Appointment
24th Feb 20217:00 amRNSInvestor update
18th Feb 20217:00 amRNSStrategy and commercial update
2nd Feb 20217:00 amRNSProposed Director appointment
19th Jan 20217:00 amRNSNew appointments
12th Jan 20217:00 amRNSChange of broker
11th Jan 20217:00 amRNSResearch study
7th Jan 20214:41 pmRNSSecond Price Monitoring Extn
7th Jan 20214:36 pmRNSPrice Monitoring Extension
5th Jan 20217:00 amRNSDirectorate Change
9th Dec 20207:00 amRNSProposed Director appointment and Director change
18th Nov 20207:00 amRNSLicense and supply agreement with Genuine Health

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.